Page 335 - Binder2

import them at inflated prices, subject to foreign patent
control and global shipping constraints.

Edible biologics offer a chance to leapfrog that gap.

A nation doesn’t need to spend $500 million building a
cGMP biomanufacturing facility to make a therapeutic
enzyme. It can grow and process plant-based versions in a
regional hub, overseen by its own regulatory body, serving
its own population.

This is biopharma sovereignty.
Not just access to drugs—but control over their
production.

Deployable Manufacturing for Emergencies

Now take this a step further: imagine a deployable unit
designed for humanitarian settings.

● A mobile plant-growth module with freeze-drying
and encapsulation stations.
● Preloaded with plant lines expressing oral cholera
vaccines, norovirus antibodies, or antivirals for viral
outbreaks.
● Operable in disaster zones, refugee camps, or low-
resource clinics.

This would make it possible to manufacture stable
biologics on site—no imports, no delays, no refrigeration.
This model could respond to emerging epidemics or
neglected diseases with unprecedented speed and
flexibility.

333